HCW Biologics
Miramar, Florida, United States · Biopharma, Biotechnology, Health Care
HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19.
Key facts
- Headquarters
- Miramar, Florida, United States
- Employees
- 35
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (HCWB)
- Website
- hcwbiologics.com
- Company page
Recent activity at HCW Biologics
- : SEC 8-K (1.01): On September 23, 2026, HCW Biologics Inc. entered into a Securities Purchase Agreement with an existing institutional investor to issue and sell 903,614 units. Each unit includes one pre-funded warrant allowing the purchase of one share of common stock and the right to receive one common stock purchase warrant, contingent on stockholder approval. The units were sold at a purchase price of $1.65 each, indicating a strategic move to raise capital for the company's development initiatives. This agreement reflects the investor's continued confidence in HCW Biologics' potential.
- : SEC 8-K (7.01): On September 9, 2026, HCW Biologics Inc. issued Amendment No. 1 to its Preliminary Proxy Statement. This amendment is a significant update related to the company's governance and provides essential information to its shareholders. The filing includes critical details that could influence voting decisions at the upcoming shareholder meeting. By filing this amendment, the Company ensures compliance with regulatory requirements and aims to enhance transparency with its investors.
- : SEC 8-K (1.01): On September 4, 2026, HCW Biologics Inc. entered into an Exclusive Distribution Agreement with Akron Biotech. This agreement is for the distribution of HCW11-006, a commercial-ready molecule intended for use as a reagent in cell therapy manufacturing and other ex vivo applications, excluding injectable therapies. The agreement covers global distribution, with the exception of the People's Republic of China. This partnership is expected to enhance HCW Biologics' market reach and operational capabilities in the biopharmaceutical sector.
- : SEC 8-K (4.02):
- : HCW Biologics
- : SEC 8-K (1.01): On July 29, 2026, HCW Biologics Inc. entered into a Securities Purchase Agreement with accredited investors to issue and sell 618,682 units, each unit comprising either one share of Common Stock or one pre-funded warrant to purchase a share of Common Stock, alongside the right to receive one Common Warrant. The Units sold at a price of $2.585 per unit, with gross proceeds anticipated to be approximately $1.6 million, will be utilized for working capital and clinical development activities. The Common Warrants, subject to stockholder approval, will have specific terms including an exercise price of $2.585 and a lifespan of five and a half years. The investment structure includes restrictions to limit beneficial ownership post-exercise and adherence to Nasdaq requirements.
- : SEC 8-K (8.01): HCW Biologics Inc. reported the settlement and extinguishment of $2.8 million in disputed accounts payable following a Voluntary Dismissal with Prejudice from B&I Contractors, Inc. on June 26, 2026. This dismissal resolved crossclaims in a legal matter related to a mechanics’ lien against the Company’s property, thus eliminating an outstanding lien of $1.1 million. This settlement marks the completion of negotiations with B&I and includes a historical settlement agreement with EirGenix, Inc., where HCW Biologics settled payments related to manufacturing costs, totaling $1.2 million paid in full as of May 26, 2026. The resolution of these matters allows the Company to move forward without these financial encumbrances, significantly impacting its operational capacity and financial clarity.
- : SEC 8-K (7.01): On June 26, 2026, HCW Biologics Inc. issued a press release announcing a Reverse Stock Split, which is considered significant for shareholders and the market. The press release indicates a strategic decision aimed at increasing the per-share price of its stock to meet exchange listing requirements. A Certificate of Amendment of Certificate of Incorporation was filed on June 24, 2026, related to this corporate action. This reverse split is expected to impact shareholder perception and possibly the liquidity of the stock. The details in the press release emphasize compliance with regulatory requirements and the company’s commitment to maintaining its listing status.
- : SEC 8-K (7.01): On June 16, 2026, HCW Biologics Inc. issued a press release announcing positive preliminary results from the first two dose cohorts of its Phase 1 clinical trial for HCW9302, an IL-2 based fusion immunotherapeutic targeting patients with alopecia areata. The announcement serves as a Regulation FD Disclosure under Item 7.01 and emphasizes the encouraging data which could have strategic implications for the clinical development of the therapy. The press release is included as Exhibit 99.1 in this Current Report on Form 8-K, highlighting key developments in HCW Biologics' ongoing research efforts.
- : HCW Biologics
HCW Biologics funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $1.5M |
| Jun 2026 | Venture | $4.0M |
| Dec 2024 | Venture | $6.9M |
| Feb 2024 | Seed | $2.5M |
| Apr 2023 | Debt Financing | $26.3M |
Leadership
- Hing Wong, Executive Officer, Director
- Rebecca Byam, Chief Financial Officer
- Peter Rhode, Executive Officer
Verified email and direct lines for HCW Biologics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
HCW Biologics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
HCW Biologics in the news
- HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter - Investing News Network (Jun 30, 2026)
- HCW Biologics Announces Pricing of $1.5 Million Private Placement - GlobeNewswire (Sep 24, 2026)
- HCW Biologics Regains Nasdaq Bid Price Compliance and Announces 1-for-6 Reverse Stock Split | HCWB Stock News - Quiver Quantitative (Jun 30, 2026)
- HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results - GlobeNewswire (Aug 14, 2026)
- HCW Biologics Inc. (HCWB) Company Profile & Facts - Yahoo Finance - Yahoo! Finance Canada (Aug 03, 2021)
- HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel - GlobeNewswire (Aug 25, 2026)
- HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results - GlobeNewswire (May 14, 2026)
- HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata - GlobeNewswire (Jun 16, 2026)
Companies similar to HCW Biologics
- Arecor Therapeutics PLC · Biopharma, Biotechnology, Health Care, Therapeutics
- Candel Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- DiaMedica Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- Windward Bio · Biopharma, Biotechnology, Health Care, Therapeutics
- BioLineRx Ltd · Biopharma, Biotechnology, Health Care, Therapeutics
About HCW Biologics: questions and answers
What does HCW Biologics do?
HCW Biologics is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19.
Where is HCW Biologics headquartered?
HCW Biologics is headquartered in Miramar, Florida, United States.
How many employees does HCW Biologics have?
HCW Biologics has about 35 employees.
Has HCW Biologics raised funding?
Yes. Fundz has recorded 5 funding events for HCW Biologics. The most recent, Post-IPO Equity of $1.5M, was in Aug 2026.
What is the latest news on HCW Biologics?
On Sep 23, 2026, SEC 8-K (1.01): On September 23, 2026, HCW Biologics Inc. entered into a Securities Purchase Agreement with an existing institutional investor to issue and sell 903,614 units. Each unit includes one pre-funded warrant allowing the purchase of one share of common stock and the right to receive one co
Is HCW Biologics a public company?
Yes. HCW Biologics is publicly traded under the ticker HCWB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy